Latest News - Clinical Trials

Thursday, October 19, 2017 | Clinical Trials, Retina, AMD, Genentech

Genentech Completes Patient Enrollment In Phase 2 Study Evaluating A New Delivery System for Lucentis

Genentech has completed enrollment in the LADDER (Long Acting Delivery of Ranibizumab) trial, a phase 2, multicenter, randomized, active treatment-controlled clinical trial investigatin…

Read the full story

Tuesday, October 17, 2017 | Clinical Trials

MeiraGTx Presents Preclinical Data on its Ocular Gene Therapy Studies for the Treatment of Leber's Congenital Amaurosis, Achromatopsia and X-Linked Retinitis Pigmentosa

MeiraGTx announced the presentation of preclinical data from studies in animal models of Leber's congenital amaurosis (LCA2), achromatopsia, and X-linked retinitis pigmentosa (XLRP) that support t…

Read the full story

Thursday, October 12, 2017 | Clinical Trials, Spark Therapeutics

FDA Advisory Committee Unanimously Recommends Approval of Luxturna for Patients with Biallelic RPE65-Mediated Inherited Retinal Disease

Spark Therapeutics announced that the FDA's Cellular, Tissue and Gene Therapies Advisory Committee has unanimously recommended (16-0) approval of Luxturna (voretigene neparvovec), an investigation…

Read the full story

Wednesday, October 11, 2017 | Clinical Trials, Medical Studies, Spark Therapeutics

Spark Gene Therapy Improves Vision, At Least in Short Term: FDA

Spark Therapeutics’s experimental gene therapy for a rare inherited form of blindness improves vision, though it is unclear whether the benefit lasts over time, according to a preliminary review…

Read the full story

Tuesday, October 10, 2017 | Clinical Trials, Medical Studies, Retina, ThromboGenics

ThromboGenics Announces Publication in Experimental Eye Research of Preclinical Data Supporting Therapeutic Potential of THR-317 in DR

ThromboGenics NV announced that preclinical data on its THR-317 have been published in Experimental Eye Research. ThromboGenics’ preclinical studies are designed to investigate inhibition of pla…

Read the full story

Monday, October 02, 2017 | Clinical Trials, Retina

Efficacy Data on Novel Treatment for Diabetic Macular Edema

Verseon presented promising preclinical efficacy results on its plasma kallikrein inhibitors for the treatment of diabetic macular edema (DME) at the fifth annual Targeting Ocular Disorders conference…

Read the full story

Thursday, September 28, 2017 | Clinical Trials, Retina

First Patient in US Receives a Telescope Implant for Age-Related Macular Degeneration After Previous Cataract Surgery

VisionCare announced that the first patient in its clinical investigation to evaluate the safety and effectiveness of exchanging a previously implanted IOL with the Implantable Miniature Telescope (by…

Read the full story

Thursday, September 28, 2017 | Clinical Trials, SciFluor Life Sciences

SciFluor Announces Positive Topline Results of Phase 1/2 Study of SF0166 Topical Ophthalmic Solution in DME Patients

SciFluor Life Sciences, a subsidiary of Allied Minds, announced positive topline results of a phase 1/2 study of SF0166, the company’s lead drug in development for the topical (eye drop) treatme…

Read the full story

Monday, September 25, 2017 | Clinical Trials

Ocugen Announces FDA Acceptance of Investigational NDA for OCU310 and Initiates Proof of Concept Study for Treatment of Dry Eye Disease

Ocugen announced that the FDA accepted its investigational new drug (IND) application for OCU310 (brimonidine/steroid combination therapy), a topical formulation for the treatment of dry eye disease (…

Read the full story

Tuesday, September 19, 2017 | Clinical Trials, Retina, AMD, GrayBug

Graybug Vision Initiates Phase 1/2 Trial of GB-102 for Wet AMD

Graybug Vision announced that it has begun dosing patients with wet AMD in its first clinical trial of GB-102, its lead product. GB-102 is a novel intravitreal (IVT) injectable depot formulation of su…

Read the full story

Tuesday, September 19, 2017 | Clinical Trials, Retina, Ophthotech

Ophthotech Provides Update on Zimura Complement Programs for Treatment of Eye Diseases

Ophthotech announced the initiation of an open-label phase 2a clinical trial of Zimura (avacincaptad pegol), the company’s complement factor C5 inhibitor, in patients with wet age-related macula…

Read the full story

Monday, September 11, 2017 | Clinical Trials, Retina, AMD, Genentech

Genentech's Lampalizumab Fails Phase 3 Study for Geographic Atrophy

Genentech announced that the primary endpoint has not been met in Spectri, the first of two phase 3 studies evaluating the safety and efficacy of lampalizumab, an investigational medicine for the trea…

Read the full story

Wednesday, September 06, 2017 | Clinical Trials, Aerie Pharmaceuticals

Aerie Pharmaceuticals Initiates Mercury 3 Clinical Trial of Roclatan in Europe

Aerie Pharmaceuticals announced the commencement of patient dosing in Mercury 3, the company’s European phase 3 clinical trial of Roclatan (netarsudil/latanoprost ophthalmic solution) 0.02%/0.00…

Read the full story

Wednesday, September 06, 2017 | Clinical Trials, Spark Therapeutics

Spark Therapeutics Announces Publication of Study Confirming Test’s Validity, Reliability, and Ability to Detect Change in Functional Vision

Spark Therapeutics announced that Clinical and Experimental Ophthalmology has published a prospective, observational study that provides robust evidence for the construct and content validity of …

Read the full story

Monday, August 28, 2017 | Clinical Trials, Retina, Second Sight Medical Products

Second Sight Receives Conditional FDA Approval to Begin First Orion Human Clinical Study

Second Sight Medical Products announced that it has received conditional approval from the FDA to begin the Orion Cortical Visual Prosthesis System feasibility clinical study. The conditional approval…

Read the full story
Load More